Congressional action is the only way to solve the uncertainty on section 101 of the US patent statute, argues Aaric Eisenstein of Personalised Media Communications
With new guidelines set to reshape patent examination, the USPTO head makes the case for revisiting subject matter precedent
Senior decision makers from a wide range of companies are already confirmed to attend as demand for tickets exceeds the rate for last year's sell-out event in San Francisco
PTAB reforms help fuel a miraculous rise up the latest International IP Index, but a recent Federal Circuit decision on eligibility highlights the serious challenges that remain - especially for life sciences companies
The Federal Circuit’s precedential judgment in Supernus Pharmaceuticals v Iancu is good news for rights holders – especially those in life sciences
Swedish company issues statement after an unsourced Chinese media article claims that a probe into its licensing practices is underway
Brand name pharmaceutical companies are facing a policy-making onslaught; with their IP strategies firmly in the spotlight, many are being forced to speak up for the rights that underpin their products.
America's life sciences innovators face accusations of using patents to build monopolies and overcharge for vital medicines. If they do not tell their side of the story and fast, they risk losing vital protections on which they rely
In a rare public appearance, the Chinese telecom’s founder and CEO, Ren Zhengfei, reaffirms commitment to respect third-party patents and explains why paying more than the competition will keep his company ahead
In exclusive interview with IAM, after confirming as a speaker for IPBC Global 2019, the former BlackBerry IP chief talks in-depth about life sciences and high tech convergence - and the many patent opportunities that creates
New IAM research reports identify the key trends shaping the global IP market – and tell you how to respond
Appointment of experienced patent litigator to local bench and Austin's growing reputation as a tech hub must be weighed against defendant-friendly rules
Services at the FDA could “grind to a halt” in a matter weeks if the budget deadlock between President Trump and Democrats continues. Major disruption at the USPTO and in the courts may also be on the cards.
Lawsuit filings and inter partes review petitions both fell in 2018, but operating companies’ share of the action was on the rise
In exclusive interview with IAM, Bill Merritt claims that ADR can prevent current licence conflict with Huawei becoming a flashpoint in the US-China trade battle